Misplaced Pages

Lisata Therapeutics

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Caladrius Biosciences) Biopharmaceutical company in New Jersey, United States
Lisata Therapeutics
Company typePublic
Traded asNasdaq: LSTA
IndustryBiopharmaceuticals
HeadquartersBasking Ridge, New Jersey, United States
Key peopleDavid J. Mazzo (CEO)
Websitelisata.com

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.

In 2019, the FDA granted their product, certepetide (also known as iRGD and CEND-1), orphan drug status in pancreatic cancer, followed by a Fast track (FDA) status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

References

  1. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics, September 15, 2022
  2. Barrie, Robert (June 29, 2022). "Cend Therapeutics' CEND-1 Granted Fast Track Designation for Pancreatic Cancer".
  3. "Certepetide (Synonyms: CEND-1; iRGD; LSTA1)". MedChemExpress. MedChemExpress. Retrieved 5 November 2024.
Categories: